Birabresib (OTX-015, MK-8628)[1] is an experimental small molecule inhibitor of BRD2, BRD3, and BRD4 under investigation for the treatment of cancer. It is in development by Merck & Co. It is currently in clinical trials for leukemia and glioblastoma.[2]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H22ClN5O2S |
Molar mass | 491.99 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Birabresib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council.
- ^ "Birabresib - OncoEthix". AdisInsight. Springer Nature Switzerland AG.